Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

Clinical trial NCT00422799 · COMPLETED

Trial details

NCT number: NCT00422799
Sponsor: Dana-Farber Cancer Institute
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Waldenstrom's Macroglobulinemia

Start date: 2006-08-30
Primary completion: 2015-10-09
Enrollment: 63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.